medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2005, Number 2

<< Back Next >>

An Med Asoc Med Hosp ABC 2005; 50 (2)

Erythropoietin effect in musculocutaneous flap. Experimental model

Said LFM, Gutiérrez SE

Language: Spanish
References: 25
Page: 66-72
PDF size: 175.15 Kb.


ABSTRACT

Erythropoietin is used for the correction of post surgery anemia or when there is a considerable calculated hematopoyetic loss. Other positive effects have been also demonstrated regarding ischemia injuries. The study was made with 30 Wistar rats assigned at random to three different groups. In all groups a TRAM type musculocutaneous flap extended bilaterally with its inferior circulation. The flap was isolated from the top section with a plastic piece. A placebo was applied to the control group; Group I application was erythropoietin 50 UI/Kg and in group II 100 UI/Kg, immediately after surgery and every 3 days during 14 days. After research ended, removal of the flap was made, graded, photographed and sent to the pathology department for testing. Measurement of hematocrit was taken at the beginning and at the end. Flap measurements were made every day. It was found that group I suffered less ischemia than control group and group II (P‹0.0001) increasing the life of the flap in group I by 80% and in group II with 60%. There was no significant increase in the hematocrit levels in any of the three study groups.


REFERENCES

  1. McCarthy J. Plastic surgery, general principles. USA: Lipckot, 1990; 275-328.

  2. McCarthy J. Plastic surgery. Territorios vasculares (angiosomas). USA: Lipckot, 1990; 329-378.

  3. Von Doersten P, Cruz RM, Selby JV, Hilsinger RL. Transfusion, recurrence and infection in head and neck cancer surgery. Otolaryngol Head Neck Surg 1992; 106: 60-67.

  4. Eschbach JW, Kelly MR, Haley NR et al. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989; 321: 158-163.

  5. Hillman RS. Las bases farmacológicas de la terapéutica. 8a ed. USA: MacGraw-Hill, 1991; 123.

  6. Jacobsen LO, Goldwasser E, Freed W et al. Role of the kidney in erythropoiesis. Nature 1957; 179: 633-634.

  7. Osgood E. A unifying concept f the etiology of the leukaemias, lymphomas and cancers. J Natl Cancer Inst 1957; 18: 155-166.

  8. Wu A, Till J, McCulloch E. A cytological study of the capacity for differentiation of normal haemopoietic colony forming cells. J Cell Physiol 1967; 69: 177-184.

  9. Bradley T, Metcalf D. The growth of mouse bone marrow cells in vitro. Aust J Exp Biol Med Sci 1966; 44: 287-300.

  10. Carnot P, Deflandre C. Sur pactivité hémopoiétique de sérum au cours de la régenération du sang. CR Acad Sci 1906; 143: 384-386.

  11. Reissmann K. Studies on the mechanism of erythropoietic stimulation in parabiotic rats during hypoxia. Blodd 1950; 5: 372-380.

  12. Powell J, Berkner K, Lebo R, Adamson J. Human erythropoietin gene: High level expression in stably transfected mammalian cells and chromosome localization. Proc Natl Acad Sci USA 1986; 83: 6465-6469.

  13. Hillman RS. Las bases farmacológicas de la terapéutica. 8a ed. USA: MacGraw-Hill, 1991; 1240.

  14. Hillman RS. Las bases farmacológicas de la terapéutica. 8a ed. USA: MacGraw-Hill, 1991; 1240-1269.

  15. Chong Z, Kang J, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial activation of cysteine proteases. J Am Heart 2002; 106 (23): 2973-2979.

  16. Parsa CJ, Matsumoto A, Kim J et al. A novel protective effect of erythropoietin in the infarcted heart. J Cl Invest 2003; 112 (7): 999-1007.

  17. Bany M, Fayez M, Slivka et al. Recombinant human erythropoietin: Possible role as an antioxidant in premature rabbits. Int Ped Res Found 1996; 40 (3): 381-387.

  18. Calapai G, Marciano M, Corica F et al. Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. Eur J Pharmacol 2000; 401: 381-387.

  19. Özgentas H, Shenaq S, Spira M. Study of the delay phenomenon in the rat TRAM flap model. Plas Recons Surg 1993; 94 (7): 1018-1024.

  20. Robbins TH. Rectus abdominis myocutaneous flap for breast reconstruction. Aust NZ J Surg 1979; 49: 527-530.

  21. Hartrampf CR, Scheflan M, Black PW. Breast reconstruction with a transverse abdominal island flap. Plast Reconstr Surg 1982; 69: 216-224.

  22. Scheflan M, Dinner M. The transverse abdominal island flap part I Indications, contraindications, results and complications. Ann Plast Surg 1983; 10: 24-35.

  23. Hamdy H, El-Mrakby, Milner R. The vascular anatomy of the lower anterior abdominal wall: A microdissection study on the deep inferior epigastric vessels and the perforator branches. Plas Reconstr Surg 2002; 109: 539-543.

  24. Moon HK, Taylor GI. The vascular anatomy of rectus abdominis musculocutaneous flaps based on the deep superior epigastric system. Plast Reconstr Surg 1988; 82: 815-829.

  25. McCarthy JJ. Plastic surgery. In: Principles and physiology of skin flan surgery. USA: Lipckot, 1990; 282-284.




2020     |     www.medigraphic.com